BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7520108)

  • 1. Pulmonary toxicity of bleomycin: is G-CSF a risk factor?
    Bastion Y; Coiffier B
    Lancet; 1994 Aug; 344(8920):474. PubMed ID: 7520108
    [No Abstract]   [Full Text] [Related]  

  • 2. Possible toxicity with the association of G-CSF and bleomycin.
    Bastion Y; Reyes F; Bosly A; Gisselbrecht C; Yver A; Gilles E; Maral J; Coiffier B
    Lancet; 1994 May; 343(8907):1221-2. PubMed ID: 7513778
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis.
    Azoulay E; Herigault S; Levame M; Brochard L; Schlemmer B; Harf A; Delclaux C
    Crit Care Med; 2003 May; 31(5):1442-8. PubMed ID: 12771616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
    Saxman SB; Nichols CR; Einhorn LH
    Chest; 1997 Mar; 111(3):657-60. PubMed ID: 9118704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of granulocyte colony-stimulating factor on experimental bleomycin-induced pulmonary fibrosis].
    Skurikhin EG; Andreeva TV; Khmelevskaia ES; Ermolaeva LA; Pershina OV; Ermakova NN; Stepanova IE; Reztsova AM; Krupin VA; Gol'dberg VE; Reĭkhart DV; Dygaĭ AM
    Eksp Klin Farmakol; 2012; 75(1):30-3. PubMed ID: 22442961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.
    Lei KI; Leung WT; Johnson PJ
    Br J Cancer; 1994 Nov; 70(5):1009-13. PubMed ID: 7524599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of screening and monitoring for bleomycin pulmonary toxicity.
    Shippee BM; Bates JS; Richards KL
    J Oncol Pharm Pract; 2016 Apr; 22(2):308-12. PubMed ID: 25736276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary toxicity during granulocyte colony stimulating factor administration and neutrophils.
    Katoh M; Takada M; Nakayama M; Umeda M
    Chest; 1996 Aug; 110(2):576-7. PubMed ID: 8697875
    [No Abstract]   [Full Text] [Related]  

  • 9. [Focus on granulocyte colony-stimulating factor-induced pulmonary toxicity].
    Noël-Savina E; Descourt R
    Bull Cancer; 2012 Feb; 99(2):211-7. PubMed ID: 22265942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.
    Ahmed BM; Al-Zakwani IS
    J Oncol Pharm Pract; 2013 Mar; 19(1):3-7. PubMed ID: 22504168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of concomitant use of Colony-Stimulating factors on bleomycin pulmonary toxicity - A systematic review and meta-analysis.
    Mahdi Seyedzadeh Sani S; Sahranavard M; Jannati Yazdanabad M; Seddigh Shamsi M; Elyasi S; Hooshang Mohammadpour A; Sathyapalan T; Arasteh O; Ghavami V; Sahebkar A
    Int Immunopharmacol; 2022 Nov; 112():109227. PubMed ID: 36099787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
    Yokose N; Ogata K; Tamura H; An E; Nakamura K; Kamikubo K; Kudoh S; Dan K; Nomura T
    Br J Cancer; 1998 Jun; 77(12):2286-90. PubMed ID: 9649147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.
    Tigue CC; McKoy JM; Evens AM; Trifilio SM; Tallman MS; Bennett CL
    Bone Marrow Transplant; 2007 Aug; 40(3):185-92. PubMed ID: 17563736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data.
    Azoulay E; Attalah H; Harf A; Schlemmer B; Delclaux C
    Chest; 2001 Nov; 120(5):1695-701. PubMed ID: 11713155
    [No Abstract]   [Full Text] [Related]  

  • 15. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
    Ho P; Sherman P; Grigg A
    Eur J Haematol; 2012 May; 88(5):416-21. PubMed ID: 22296221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure.
    Bennett WM; Pastore L; Houghton DC
    Cancer Treat Rep; 1980; 64(8-9):921-4. PubMed ID: 6160913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
    Martin WG; Ristow KM; Habermann TM; Colgan JP; Witzig TE; Ansell SM
    J Clin Oncol; 2005 Oct; 23(30):7614-20. PubMed ID: 16186594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of the pulmonary toxicity of continuously infused bleomycin.
    Cooper KR; Hong WK
    Cancer Treat Rep; 1981; 65(5-6):419-25. PubMed ID: 6165471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of granulocyte colony-stimulating factor on the kinetics of inflammatory cells in the peripheral blood and pulmonary lesions during the development of bleomycin-induced lung injury in rats.
    Adachi K; Suzuki M; Sugimoto T; Uetsuka K; Nakamaya H; Doi K
    Exp Toxicol Pathol; 2003 Jul; 55(1):21-32. PubMed ID: 12940625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
    Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
    Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.